Jazz Pharmaceuticals plc (JAZZ) surged 21.59%, closing at $171.52, up $30.45, after announcing the Phase 3 HERIZON-GEA-01 trial of its drug Ziihera (zanidatamab-hrii) plus chemotherapy, with or without tislelizumab, showed statistically significant improvements in both progression-free survival - PFS and overall survival - OS versus trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma.
The company plans to submit a supplemental Biologics License Application - sBLA in the first half of 2026. On the same day, Jazz also showcased new clinical and translational data across its pipeline, highlighting advances in HER2-targeted therapies and neuro-oncology assets, underscoring its expanding oncology platform.
JAZZ experienced unusually heavy trading volume as investors absorbed the trial results and pipeline momentum. The stock's 52-week range is $89.34 - $172.10.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.